Markets:

Overview

News

Currencies

International

Treasuries

Edesa Biotech, Inc. - Common Shares (NQ:EDSA)

7.610 +0.140 (+1.87%)

Streaming Delayed Price Updated: 9:54 AM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech, Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >

Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session ↗

December 22, 2022

Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

December 20, 2022

Via ACCESSWIRE

Edesa Biotech Adds Mechanically Ventilated Patients To Late-Stage COVID-19 Study ↗

May 24, 2022

Via Benzinga

Edesa Biotech Reports Fiscal Year 2022 Results

December 16, 2022

Via ACCESSWIRE

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

December 02, 2022

Via ACCESSWIRE

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

November 03, 2022

Via ACCESSWIRE

What Is Going on With Edesa Biotech (EDSA) Stock Today? ↗

September 30, 2022

Edesa Biotech released encouraging Phase 2 results for its respiratory-syndrome-targeting antibody, thus initially boosting EDSA stock.

Via InvestorPlace

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

September 30, 2022

Via ACCESSWIRE

Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday ↗

October 03, 2022

Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.

Via Benzinga

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

September 08, 2022

Via ACCESSWIRE

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

September 07, 2022

Via ACCESSWIRE

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

August 12, 2022

Via ACCESSWIRE

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

August 03, 2022

Via ACCESSWIRE

Edesa Biotech to Present at ARDS Drug Development Summit

July 11, 2022

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par...

From Edesa Biotech

Via AccessWire

Stocks That Hit 52-Week Lows On Tuesday ↗

June 28, 2022

On Tuesday, 87 companies hit new 52-week lows.

Via Benzinga

Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

May 24, 2022

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the...

From Edesa Biotech

Via AccessWire

Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

May 19, 2022

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par...

From Edesa Biotech

Via AccessWire

Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

May 13, 2022

TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...

From Edesa Biotech

Via AccessWire

Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

April 28, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From Edesa Biotech

Via AccessWire

Edesa Biotech Appoints Strategy Expert to Board of Directors

March 29, 2022

TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the...

From Edesa Biotech

Via AccessWire

Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

March 24, 2022

TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the...

From Edesa Biotech

Via AccessWire

66 Biggest Movers From Yesterday ↗

March 23, 2022

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement. Forge Global...

Via Benzinga

Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 22, 2022

TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it...

From Edesa Biotech

Via AccessWire

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

February 17, 2022

TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an...

From Edesa Biotech

Via AccessWire

Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

February 14, 2022

TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported...

From Edesa Biotech

Via AccessWire

Edesa Biotech to Join Ontario Bioscience Panel Discussion

January 26, 2022

TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr....

From Edesa Biotech

Via AccessWire

Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy ↗

January 13, 2022

Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically...

Via Benzinga

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

January 13, 2022

- Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a...

From Edesa Biotech

Via AccessWire

5 Stocks To Watch For Wednesday, December 29, 2021 ↗

December 29, 2021

5 stocks you that you should keep in mind today.

Via Talk Markets

5 Stocks To Watch For December 29, 2021 ↗

December 29, 2021

Some of the stocks that may grab investor focus today are: Cal-Maine Foods (NASDAQ: CALM) reported weaker-than-expected earnings for its second quarter on Tuesday. Cal-Maine...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Contact Us

Contact Us

Edesa Biotech, Inc. - Common Shares (NQ:EDSA)

All News about Edesa Biotech, Inc. - Common Shares